View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 14, 2020

Update on clinical trials disrupted due to Covid-19

By Victoria Smith

Since the beginning of March, a large number of companies acting as a collaborator, sponsor, or CRO publically declared disruptions to planned and ongoing clinical trials on SEC filings, press releases and clinical trial registries, as well as on social media. Businesses have delayed commencement of planned trials, with some withdrawing them completely. Furthermore, enrolment has been suspended in ongoing trials, while others have been terminated completely.

The Covid-19 Dashboard on the Pharma Intelligence Center dynamically tracks these interrupted trials from the Clinical Trials Database, as well as the list of companies connected to these trials. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena